Business Description
StemRIM Inc
ISIN : JP3399690001
Description
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16457.38 | |||||
| Equity-to-Asset | 0.98 | |||||
| Piotroski F-Score | 6/9 | |||||
| Beneish M-Score | 86.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.7 | |||||
| 3-Year EBITDA Growth Rate | -17 | |||||
| 3-Year EPS without NRI Growth Rate | -26.4 | |||||
| 3-Year FCF Growth Rate | 37.5 | |||||
| 3-Year Book Growth Rate | -3.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.52 | |||||
| 9-Day RSI | 62.66 | |||||
| 14-Day RSI | 57.68 | |||||
| 6-1 Month Momentum % | -18.81 | |||||
| 12-1 Month Momentum % | -42.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 100.08 | |||||
| Quick Ratio | 99.9 | |||||
| Cash Ratio | 93.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.3 | |||||
| Shareholder Yield % | 0.01 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | 48.3 | |||||
| ROE % | -21.16 | |||||
| ROA % | -20.59 | |||||
| ROIC % | -196.23 | |||||
| 3-Year ROIIC % | -3923.46 | |||||
| ROC (Joel Greenblatt) % | -214.54 | |||||
| ROCE % | -20.89 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 48.93 | |||||
| PS Ratio | 11.93 | |||||
| PB Ratio | 2.94 | |||||
| Price-to-Tangible-Book | 2.94 | |||||
| Price-to-Free-Cash-Flow | 24.71 | |||||
| Price-to-Operating-Cash-Flow | 24.7 | |||||
| EV-to-EBIT | -8.84 | |||||
| EV-to-EBITDA | -8.84 | |||||
| EV-to-Revenue | 8.01 | |||||
| EV-to-FCF | 15.34 | |||||
| Price-to-Net-Current-Asset-Value | 3.01 | |||||
| Price-to-Net-Cash | 3.23 | |||||
| Earnings Yield (Greenblatt) % | -11.29 | |||||
| FCF Yield % | 4.11 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers